Earnings · US stocks

Arrowhead Pharmaceuticals, Inc. (ARWR) earnings

Arrowhead Pharmaceuticals, Inc. published its quarterly report on 2026-11-12. The stock moved -8.82% in the 3 trading days after the report.

Report
quarterly report
Published
2026-11-12
Result
Bad / loss
Open earnings in Wave Radar

Stock move after the report

Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.

AfterReturnvs index
1 day+1.34%—
3 days-8.82%—

Report history

Over the last 8 reports, EPS beat the consensus estimate in 3 of them. The stock rose in the 3 trading days after 4 of 8 reports (average +3.07%).

PublishedEPS YoYEPSEPS surprise3 days after30 days after30d vs index
2026-11-12—-1.52-1.20%-8.82%——
2026-08-04—-1.36-10.35%-2.17%-26.57%-24.33%
2026-05-07-133.80%-0.93+15.98%+1.40%+5.20%+3.44%
2026-02-05—0.22+159.86%-2.66%-12.86%-8.57%
2025-11-25—-0.18-14.45%+20.22%+37.98%+35.16%
2025-08-07—-1.26-14.41%+10.83%+91.10%+86.12%
2025-05-12—2.75+695.04%+9.81%+12.10%+7.96%
2025-02-10—-1.39-92.16%-4.07%-26.05%-21.20%

The last 8 reported quarters. Moves count trading days from the first tradeable session after the report; "30d vs index" is the excess return over the market index.

Stock valuations: ARWR

How to read this

Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.